Marco Carbone Selected Research

Ursodeoxycholic Acid (Urso)

12/2023	Prognostic models and autoimmune liver diseases.
10/2023	Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis.
7/2023	Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
1/2023	Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.
4/2021	Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
1/2021	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
12/2019	The challenges of primary biliary cholangitis: What is new and what needs to be done.
1/2019	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
5/2018	NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.
1/2018	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marco Carbone Research Topics

Disease

40	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 10/2023 - 06/2011
13	Fibrosis (Cirrhosis) 01/2023 - 01/2010
10	Liver Diseases (Liver Disease) 01/2023 - 01/2014
8	Sclerosing Cholangitis 12/2023 - 06/2011
6	Fatigue 01/2023 - 03/2013
5	Liver Cirrhosis (Hepatic Cirrhosis) 12/2023 - 01/2011
5	Disease Progression 11/2022 - 08/2016
5	Infections 05/2022 - 01/2011
5	Autoimmune Hepatitis 01/2022 - 01/2014
5	Cholestasis 01/2021 - 08/2008
3	Liver Failure 01/2023 - 08/2012
3	End Stage Liver Disease 01/2022 - 01/2010
3	Autoimmune Diseases (Autoimmune Disease) 08/2017 - 04/2014
3	Hepatitis C 08/2012 - 01/2010
2	Ascites 11/2022 - 01/2021
2	Hepatocellular Carcinoma (Hepatoma) 05/2022 - 01/2011
2	COVID-19 01/2021 - 09/2020
2	Pruritus (Itching) 01/2021 - 03/2013
2	Reperfusion Injury 12/2012 - 08/2008
1	Postpartum Depression (Post-Natal Depression) 02/2024
1	Hip Dislocation 08/2023
1	Pain (Aches) 08/2023
1	Non-alcoholic Fatty Liver Disease 05/2023
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2023
1	Inflammation (Inflammations) 01/2023
1	Acute-On-Chronic Liver Failure 01/2023
1	Chronic Disease (Chronic Diseases) 11/2022
1	Ankylosing Spondylitis 09/2022
1	Rare Diseases (Rare Disease) 09/2022
1	Nephrotic Syndrome (Syndrome, Nephrotic) 09/2022
1	Rheumatoid Arthritis 09/2022
1	Persistent Infection 09/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 09/2022
1	Insulin Resistance 05/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Rheumatic Diseases (Rheumatism) 01/2022
1	Pneumonia (Pneumonitis) 01/2021
1	Esophageal and Gastric Varices (Esophageal Varices) 01/2021
1	Takayasu Arteritis (Arteritis, Takayasu's) 01/2021
1	Mucopolysaccharidosis I (Hurler Syndrome) 01/2019
1	Dysostoses 01/2019
1	Metaplasia 12/2018
1	Mucopolysaccharidoses 11/2018
1	Hyper-IgM Immunodeficiency Syndrome (Hyper-IgM Syndrome) 01/2018
1	Bile Duct Diseases (Bile Duct Disease) 01/2018
1	Primary Immunodeficiency Diseases 01/2018

Drug/Important Bio-Agent (IBA)

13	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 12/2023 - 03/2013
9	Alkaline PhosphataseIBA 07/2023 - 08/2017
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2009
5	AutoantibodiesIBA 01/2023 - 12/2016
5	obeticholic acidIBA 12/2022 - 06/2020
5	BilirubinIBA 12/2022 - 01/2020
3	Bile Acids and Salts (Bile Acids)IBA 01/2022 - 08/2017
2	Immunoglobulin G (IgG)IBA 01/2023 - 07/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 01/2021
2	setanaxibIBA 01/2023 - 01/2023
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2022 - 03/2013
2	Alanine Transaminase (SGPT)IBA 12/2022 - 03/2013
2	SteroidsIBA 09/2020 - 06/2020
2	InterferonsIBA 01/2015 - 04/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2014 - 01/2009
1	Tuberculin (PPD)IBA 02/2024
1	GlucocorticoidsIBA 08/2023
1	Analgesics (Analgesic Drugs)IBA 08/2023
1	Glucose (Dextrose)FDA LinkGeneric 05/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	NADPH Oxidase 1IBA 01/2023
1	Vancomycin FDA LinkGeneric 01/2023
1	AlbuminsIBA 11/2022
1	AA amyloidosisIBA 09/2022
1	mRNA VaccinesIBA 01/2022
1	VaccinesIBA 01/2022
1	AvidinIBA 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Nucleic AcidsIBA 01/2022
1	SuspensionsIBA 04/2021
1	Fibric Acids (Fibrates)IBA 01/2021
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2021
1	TransferasesIBA 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	EnzymesIBA 09/2020
1	Mannose ReceptorIBA 01/2020
1	Antinuclear AntibodiesIBA 07/2019
1	AntibodiesIBA 07/2019
1	Interleukin-12 Receptors (Interleukin 12 Receptor)IBA 07/2019
1	Bicarbonates (Hydrogen Carbonate)IBA 01/2019
1	Secretin FDA Link 01/2019
1	secretin receptorIBA 01/2019
1	GlycosaminoglycansIBA 11/2018
1	Chemokine CXCL10IBA 05/2018
1	Immunoglobulin M (IgM)IBA 01/2018
1	Serum AlbuminIBA 01/2018

Therapy/Procedure

20	Liver Transplantation 12/2023 - 01/2010
16	Therapeutics 12/2023 - 03/2013
6	Precision Medicine 01/2022 - 08/2016
5	Transplantation 05/2022 - 01/2010
1	Critical Care (Surgical Intensive Care) 01/2023
1	Activities of Daily Living (ADL) 01/2019
1	Intravenous Administration 05/2018